cytarabine accord
accord healthcare b.v. - citarabinas - injekcinis ar infuzinis tirpalas - 100 mg/ml - cytarabine
bendamustine accord
accord healthcare b.v. - bendamustino hidrochloridas - milteliai infuzinio tirpalo koncentratui - 2,5 mg/ml - bendamustine
esmocard lyo
orpha-devel handels und vertriebs gmbh - esmololis - milteliai infuzinio tirpalo koncentratui - 100 mg/10 ml; 2500 mg - esmolol
epirubicin accord
accord healthcare b.v. - epirubicino hidrochloridas - injekcinis ar infuzinis tirpalas - 2 mg/ml - epirubicin
ofost
as grindeks - oksitocinas - injekcinis ar infuzinis tirpalas - 5 tv/ml - oxytocin
ofost
as grindeks - oksitocinas - injekcinis ar infuzinis tirpalas - 10 tv/ml - oxytocin
dacepton
ever neuro pharma gmbh - apomorfino hidrochloridas hemihidratas - infuzinis tirpalas - 10 mg/ml; 5 mg/ml - apomorphine
oxaliplatin actavis
actavis group ptc ehf. - oksaliplatina - koncentratas infuziniam tirpalui - 5 mg/ml - oxaliplatin
tafinlar
novartis europharm limited - dabrafenib mesilate - melanoma - antinavikiniai vaistai - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ir 5. oksaliplatina melanomadabrafenib kartu su trametinib yra nurodyta, kad oksaliplatina suaugusiems pacientams, sergantiems iii stadijos melanoma su braf v600 mutacija, taip užbaigti rezekcija. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
topotecan accord
accord healthcare b.v. - topotekanas - koncentratas infuziniam tirpalui - 1 mg/ml - topotecan